Company Description
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection.
Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products.
Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems.
The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally.
Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1989 |
| IPO Date | Aug 16, 1995 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 4,396 |
| CEO | Mojdeh Poul |
Contact Details
Address: 1100 Campus Road Princeton, New Jersey 08540 United States | |
| Phone | 609 275 0500 |
| Website | integralife.com |
Stock Details
| Ticker Symbol | IART |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000917520 |
| CUSIP Number | 457985208 |
| ISIN Number | US4579852082 |
| Employer ID | 51-0317849 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mojdeh Poul | President, Chief Executive Officer and Director |
| Dr. Stuart M. Essig Ph.D. | Non- Executive Chairman |
| Lea Daniels Knight | Executive Vice President and Chief Financial Officer |
| Jeffrey A. Mosebrook | Senior Vice President of Finance and Principal Accounting Officer |
| Eric Ian Schwartz J.D. | Executive Vice President, Chief Legal Officer and Secretary |
| Robert T. Davis Jr. | Executive Vice President and President of Tissue Technologies |
| Michael J. McBreen | Executive Vice President and President of Codman Specialty Surgical |
| Stephen Leonard | Corporate Vice President of Global Operations and Supply Chain |
| Christopher Ward | Senior Director of Investor Relations |
| Laurene Isip | Vice President of Global Corporate Communications and Public Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 3, 2024 | 144 | Filing |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |